General Archive
-
News releasesLifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients
Seed funding will be used to scale the solution through the application of machine learning
-
News releasesPromising new antibody treatment for osteoporosis and multiple sclerosis
The new antibody offers hope of an effective new treatment option for millions of people.
-
News releasesNew £30 million translational partnership will accelerate development of new treatments for people with dementia
Funding will accelerate development of new diagnostic tests, treatments, and devices for people with dementia.
-
News releasesPromising new asthma medicine ready to enter early clinical trials
LifeArc scientists instrumental to the development of the world’s first anti-IL17BR antibody, now being trialled as a treatment for severe…
-
News releasesLifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
LONDON, UK, 17 May 2022 — LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has…
-
News releasesNew study explores unique approach to treat a rare liver disease
A research study looking into a new approach to treat primary sclerosing cholangitis (PSC) is progressing to clinical trials.
-
News releasesNew approach provides potential vaccine and treatment for Alzheimer’s
An antibody-based treatment and protein-based vaccine reduced Alzheimer’s symptoms in mouse models of the disease.
-
News releasesInnovative gene therapy programme paves the way for new treatments for neurodegenerative diseases
Funding for pioneering research by University of Sheffield in collaboration with the Cell and Gene Therapy Catapult
-
News releasesLifeArc publishes expert advice to support work around repurposing medicines
Guide will support researchers and charities who focus on diseases which have few effective therapies
-
News releasesLifeArc and MRC partnership creates new £16m fund to establish Gene Therapy Innovation Hubs
Hubs aim to address challenges in progressing novel gene therapy research into early stage clinical trials
-
News releasesLifeArc monetises Keytruda® royalty interests to fund further research and investment
LifeArc receives US$1.3bn for a portion of royalty interests in Keytruda (pembrolizumab), making us one of the UK’s leading medical…
-
News releases
Keytruda receives another breakthrough designation
Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has…